Literature DB >> 12715262

GABA receptors, progesterone and premenstrual dysphoric disorder.

I Sundström Poromaa1, S Smith, M Gulinello.   

Abstract

Premenstrual dysphoric disorder (PMDD) is characterized by depression, anxiety and other affective symptoms which recur in the luteal phase of the menstrual cycle. Evidence from animal models of depression and anxiety indicate the importance of neuroactive steroid hormones and the GABA(A) receptor in the etiology and potential treatment of mood disorders. These data are reviewed in the light of human clinical studies and specific animal models of PMDD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715262     DOI: 10.1007/s00737-002-0147-1

Source DB:  PubMed          Journal:  Arch Womens Ment Health        ISSN: 1434-1816            Impact factor:   3.633


  28 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

2.  Ovarian hormones and borderline personality disorder features: Preliminary evidence for interactive effects of estradiol and progesterone.

Authors:  Tory A Eisenlohr-Moul; C Nathan DeWall; Susan S Girdler; Suzanne C Segerstrom
Journal:  Biol Psychol       Date:  2015-03-30       Impact factor: 3.251

3.  Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder.

Authors:  Cynthia Neill Epperson; Brian Pittman; Kathryn Ann Czarkowski; Stephanie Stiklus; John Harrison Krystal; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2007-02-21       Impact factor: 7.853

4.  Increased childhood abuse in patients with premenstrual dysphoric disorder in a Turkish sample: a cross-sectional study.

Authors:  Esra Akyol Soydas; Yakup Albayrak; Basak Sahin
Journal:  Prim Care Companion CNS Disord       Date:  2014-07-24

5.  Cortical 3 alpha-hydroxy-5 alpha-pregnan-20-one levels after acute administration of Delta 9-tetrahydrocannabinol, cocaine and morphine.

Authors:  A Chistina Grobin; Margaret J VanDoren; Linda J Porrino; A Leslie Morrow
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

6.  Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder.

Authors:  Andrea J Rapkin; Steven M Berman; Mark A Mandelkern; Daniel H S Silverman; Melinda Morgan; Edythe D London
Journal:  Biol Psychiatry       Date:  2010-11-18       Impact factor: 13.382

Review 7.  Potential hormonal mechanisms of attention-deficit/hyperactivity disorder and major depressive disorder: a new perspective.

Authors:  Michelle M Martel; Kelly Klump; Joel T Nigg; S Marc Breedlove; Cheryl L Sisk
Journal:  Horm Behav       Date:  2009-03-02       Impact factor: 3.587

8.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

Review 9.  Allopregnanolone as a mediator of affective switching in reproductive mood disorders.

Authors:  Crystal Edler Schiller; Peter J Schmidt; David R Rubinow
Journal:  Psychopharmacology (Berl)       Date:  2014-05-21       Impact factor: 4.530

Review 10.  Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol.

Authors:  Istvan Mody
Journal:  Neurochem Int       Date:  2007-07-17       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.